Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine

James K. Wamsley, Donald R. Gehlert, William R. Roeske, Henry I. Yamamura

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Saturable, high affinity binding of tritiated pirenzepine ([3H]-PZ) was obtained in slide mounted tissue sections prior to performing autoradiographic localization of these binding sites. The binding in tissue sections of rostral rat forebrain gave a KD of 18nM and a Bmax of 51 fmoles/mg tissue. These binding characteristics are similar to those previously obtained in homogenate membrane preparations and indicate the binding is taking place in a similar manner. The distribution of the binding sites labeled with [3H]-PZ represented a subpopulation of those which could be labeled with tritiated quinuclidinyl benzilate ([3H]-QNB). Thus, [3H]-PZ and [3H]-QNB both label regions of the cerebral cortex, hippocampus, striatum and dorsal horn of the spinal cord, while sites in the cerebellum, nucleus tractus solitarius, facial nucleus and ventral horn of the spinal cord are labeled with [3H]-QNB and not by [3H]-PZ. These observations indicate separate regions of the brain where antagonists bind to subtypes of muscarinic receptors.

Original languageEnglish (US)
Pages (from-to)1395-1402
Number of pages8
JournalLife Sciences
Volume34
Issue number14
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Pirenzepine
Muscarinic Antagonists
Autoradiography
Labeling
Binding Sites
Tissue
Quinuclidinyl Benzilate
Solitary Nucleus
Muscarinic Receptors
Prosencephalon
Cerebral Cortex
Cerebellum
Rats
Labels
Hippocampus
Brain
Membranes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine. / Wamsley, James K.; Gehlert, Donald R.; Roeske, William R.; Yamamura, Henry I.

In: Life Sciences, Vol. 34, No. 14, 1984, p. 1395-1402.

Research output: Contribution to journalArticle

@article{b0ee08d4d8594fa59e0ecff57374e061,
title = "Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine",
abstract = "Saturable, high affinity binding of tritiated pirenzepine ([3H]-PZ) was obtained in slide mounted tissue sections prior to performing autoradiographic localization of these binding sites. The binding in tissue sections of rostral rat forebrain gave a KD of 18nM and a Bmax of 51 fmoles/mg tissue. These binding characteristics are similar to those previously obtained in homogenate membrane preparations and indicate the binding is taking place in a similar manner. The distribution of the binding sites labeled with [3H]-PZ represented a subpopulation of those which could be labeled with tritiated quinuclidinyl benzilate ([3H]-QNB). Thus, [3H]-PZ and [3H]-QNB both label regions of the cerebral cortex, hippocampus, striatum and dorsal horn of the spinal cord, while sites in the cerebellum, nucleus tractus solitarius, facial nucleus and ventral horn of the spinal cord are labeled with [3H]-QNB and not by [3H]-PZ. These observations indicate separate regions of the brain where antagonists bind to subtypes of muscarinic receptors.",
author = "Wamsley, {James K.} and Gehlert, {Donald R.} and Roeske, {William R.} and Yamamura, {Henry I.}",
year = "1984",
doi = "10.1016/0024-3205(84)90012-2",
language = "English (US)",
volume = "34",
pages = "1395--1402",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine

AU - Wamsley, James K.

AU - Gehlert, Donald R.

AU - Roeske, William R.

AU - Yamamura, Henry I.

PY - 1984

Y1 - 1984

N2 - Saturable, high affinity binding of tritiated pirenzepine ([3H]-PZ) was obtained in slide mounted tissue sections prior to performing autoradiographic localization of these binding sites. The binding in tissue sections of rostral rat forebrain gave a KD of 18nM and a Bmax of 51 fmoles/mg tissue. These binding characteristics are similar to those previously obtained in homogenate membrane preparations and indicate the binding is taking place in a similar manner. The distribution of the binding sites labeled with [3H]-PZ represented a subpopulation of those which could be labeled with tritiated quinuclidinyl benzilate ([3H]-QNB). Thus, [3H]-PZ and [3H]-QNB both label regions of the cerebral cortex, hippocampus, striatum and dorsal horn of the spinal cord, while sites in the cerebellum, nucleus tractus solitarius, facial nucleus and ventral horn of the spinal cord are labeled with [3H]-QNB and not by [3H]-PZ. These observations indicate separate regions of the brain where antagonists bind to subtypes of muscarinic receptors.

AB - Saturable, high affinity binding of tritiated pirenzepine ([3H]-PZ) was obtained in slide mounted tissue sections prior to performing autoradiographic localization of these binding sites. The binding in tissue sections of rostral rat forebrain gave a KD of 18nM and a Bmax of 51 fmoles/mg tissue. These binding characteristics are similar to those previously obtained in homogenate membrane preparations and indicate the binding is taking place in a similar manner. The distribution of the binding sites labeled with [3H]-PZ represented a subpopulation of those which could be labeled with tritiated quinuclidinyl benzilate ([3H]-QNB). Thus, [3H]-PZ and [3H]-QNB both label regions of the cerebral cortex, hippocampus, striatum and dorsal horn of the spinal cord, while sites in the cerebellum, nucleus tractus solitarius, facial nucleus and ventral horn of the spinal cord are labeled with [3H]-QNB and not by [3H]-PZ. These observations indicate separate regions of the brain where antagonists bind to subtypes of muscarinic receptors.

UR - http://www.scopus.com/inward/record.url?scp=0021354596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021354596&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(84)90012-2

DO - 10.1016/0024-3205(84)90012-2

M3 - Article

C2 - 6546776

AN - SCOPUS:0021354596

VL - 34

SP - 1395

EP - 1402

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 14

ER -